[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 24/31, 2005

Risk of Death With Nesiritide—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(8):897-898. doi:10.1001/jama.294.8.898-a

In Reply: The letters by Dr Burger and by Drs Gortney and Porter raise concerns about imbalances between groups in VMAC.1 Although some of these may be relevant, with 19 comparisons made in baseline characteristics in VMAC, it is not surprising that there would be differences noted. However, our analysis accounts for differences in the use of dobutamine as a concomitant therapy within VMAC, where its use was not a significant predictor of survival. Dobutamine was not permitted during the placebo-controlled phase of either PROACTION or NSGET.2

First Page Preview View Large
First page PDF preview
First page PDF preview